For example, tamoxifen was the first targeted therapy using estrogen receptor (ER) as the target, which is present in about 80% of all breast cancer (ER-positive), and reduces greatly the incidence of breast cancer death and recurrence in ER-positive patients. Here, ESR1 is linked to breast carcinoma.